AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19116919
Drug: Resolved CIL
RxNorm normalized name: penicillin V potassium Oral Capsule [V-Cil-K]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resolved CIL after anti-TNF treatment
Trial: 11212971
Drug: Mibefradil 50
RxNorm normalized name: mibefradil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mibefradil 50 mg daily for 2 weeks, then 100 mg daily for 4 weeks
Trial: 11212971
Drug: Nifedipine 30
RxNorm normalized name: nifedipine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 30 mg daily for 2 weeks, then 60 mg daily for 4 weeks
Trial: 8086844
Drug: Workshop on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Workshop on medical ethics for family medicine preceptors
Trial: 25011982
Drug: Flutamide treatment
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide treatment (GD50F)
Trial: 25011982
Drug: Flutamide treatment
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide treatment (GD90F)
Trial: 25011982
Drug: Flutamide treatment
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide treatment (GD108F)
Trial: 22236137
Drug: olanzapine-LAI 210
RxNorm normalized name: olanzapine 210 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine-LAI 210 mg/2 weeks
Trial: 22236137
Drug: olanzapine-LAI 300
RxNorm normalized name: olanzapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine-LAI 300 mg/2 weeks
Trial: 22236137
Drug: olanzapine-LAI 405
RxNorm normalized name: olanzapine 405 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine-LAI 405 mg/4 weeks
Trial: 9141002
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine 40 micrograms
Trial: 9141002
Drug: Hepatitis B
RxNorm normalized name: HEPATITIS B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis B vaccine 20 micrograms
Trial: 9141002
Drug: rHuIL‐2 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuIL‐2 administration (500,000 U)
Trial: 31647032
Drug: Fast-track multidisciplinary
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast-track multidisciplinary treatment (FTMDT) with fast-track perioperative treatment and XELOX adjuvant chemotherapy
Trial: 31647032
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with conventional perioperative treatment and mFOLFOX6 adjuvant chemotherapy
Trial: 25643024
Drug: Adults discounting
RxNorm normalized name: OC 8 Adult Acne
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults discounting cannabis over treatment
Trial: 25643024
Drug: Adolescents discounting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescents discounting cannabis over treatment
Trial: 19828211
Drug: Pramiconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramiconazole (200 mg taken once, and 200 mg taken once daily for 2 or 3 days)
Trial: 17093160
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 5.8 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Trial: 17093160
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 7.3 mg . kg(‐1) . d(‐1) with excess cysteine (21 mg . kg(‐1) . d(‐1))
Trial: 17093160
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 12.9 mg . kg(‐1) . d(‐1) without dietary cysteine
Trial: 17093160
Drug: Methionine intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methionine intake of 17.2 mg . kg(‐1) . d(‐1) without dietary cysteine
Trial: 15897725
Drug: intensive psychosocial
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensive psychosocial relapse‐prevention program + anxiety treatment program (CBT + optional SSRI)
Trial: 9663809
Drug: L-N(G)-monomethyl-arginine (L-NMMA)
RxNorm normalized name: .alpha.N-(methoxycarbonyl)-L-arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-N(G)-monomethyl-arginine (L-NMMA) infusion
Trial: 7831064
Drug: Defibrotide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defibrotide (400 mg tablet bid)
Trial: 7831064
Drug: Mesoglycan (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesoglycan (24 mg tablet bid)
Trial: 3343933
Drug: APM-sweetened beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APM-sweetened beverage (10 mg APM/kg body weight per serving)
Trial: 24498810
Drug: Hyoscine‐N‐butylbromide 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyoscine‐N‐butylbromide 40 mg intravenously
Trial: 9324175
Drug: Atropine 0.5
RxNorm normalized name: homatropine 0.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine 0.5 mg intravenously
Trial: 21258894
Drug: Chinese drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese drugs for supporting essence and strengthening Pi (SESP)
Trial: 21258894
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy + SESP
Trial: 19692062
Drug: Continuous epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous epidural analgesia with a loading dose of 0.25% bupivacaine or 0.2% ropivacaine, followed by continuous drip 0.2% ropivacaine
Trial: 19692062
Drug: Nonepidural analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonepidural analgesia with intraoperative morphine and postoperative oxycodone or tramadol plus ibuprofen or paracetamol for 48 hours
Trial: 17005508
Drug: No inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No inhaled anaesthetics
Trial: 9239455
Drug: Granular formulation
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular formulation of lornoxicam (8 mg)
Trial: 9239455
Drug: Standard tablets
RxNorm normalized name: Stangard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard tablets of lornoxicam (8 mg)
Trial: 8513660
Drug: Computerized pharmacokinetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized pharmacokinetic program for adjusting theophylline infusion rates
Trial: 29899015
Drug: Incentive arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Incentive arm with personalized step goals and daily feedback for 24 weeks
Trial: 26519995
Drug: Adjustable intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjustable intravenous loop diuretics (ALD)
Trial: 10449884
Drug: Aspirin with
RxNorm normalized name: Bayer Aspirin with Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin with thrombolytic treatment
Trial: 10449884
Drug: Aspirin without
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin without thrombolytic treatment
Trial: 1688487
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of AOAA four times a day for 1 week
Trial: 318978
Drug: Amoxycillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (500 mg, three times a day for 10 days)
Trial: 318978
Drug: Co-trimoxazole (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (up to 480 mg trimethoprim and 2,400 mg sulphamethoxazole daily for males, two thirds of this dose for females)
Trial: 28797783
Drug: tbo-filgrastim (Granix)
RxNorm normalized name: tbo-filgrastim Injection [Granix]
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: tbo-filgrastim (Granix) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Trial: 28797783
Drug: filgrastim (Neupogen)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: filgrastim (Neupogen) 10 µg/kg/day administered subcutaneously for 5 days in combination with plerixafor (0.24 mg/kg on day 4)
Trial: 20381664
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (first prescriptions)
Trial: 20381664
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (second prescriptions)
Trial: 12056785
Drug: 20% alanyl-glutamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% alanyl-glutamine infusion of 0.5 g/kg
Trial: 1730080
Drug: A +
RxNorm normalized name: Vital E- A + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A + I (cytarabine 100 mg/m2/d + idarubicin 13 mg/m2/d)
Trial: 1730080
Drug: A +
RxNorm normalized name: Vital E- A + D3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A + D (cytarabine 100 mg/m2/d + daunorubicin 45 mg/m2/d)
Trial: 6085363
Drug: Nifedipine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (40 mg)
Trial: 3158125
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Nifedipine and Acebutolol
Trial: 27331824
Drug: l-leucine (LEU)
DrugBank: Leucine (DB00149)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-leucine (LEU)
Trial: 21432578
Drug: manualized cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manualized cognitive-behavioural group psychotherapy plus open methylphenidate treatment
Trial: 17458426
Drug: Topical cetirizine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cetirizine dinitrate (4.4 mg twice daily)
Trial: 17458426
Drug: Oral cetirizine
RxNorm normalized name: cetirizine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cetirizine dihydrochloride (10 mg once daily)
Trial: 14694177
Drug: Low-dose cyclosporine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclosporine (CsA) and sirolimus (SRL); group 1
Trial: 14694177
Drug: Full-dose cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose cyclosporine (CsA) and mycophenolate mofetil; group 2
Trial: 11215542
Drug: Standard after-care
RxNorm normalized name: DIMETHICONE 4 mg in 1 mL TOPICAL CREAM [AFTER CARE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard after-care treatment (comparison group)
Trial: 25407559
Drug: O(6)-benzylguanine (O(6)-BG)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O(6)-benzylguanine (O(6)-BG) + BCNU 40 mg/m² + radiation therapy (RT)
Trial: 25407559
Drug: BCNU 200
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCNU 200 mg/m² + RT
Trial: 24267123
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin hydrochloride 0.4 mg
Trial: 24267123
Drug: Tamsulosin hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg
Trial: 15542510
Drug: Helicobacter pylori
RxNorm normalized name: HELICOBACTER PYLORI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Helicobacter pylori testing plus eradication therapy
Trial: 11583187
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus doxorubicin (A) combination therapy
Trial: 28449631
Drug: Dexmedetomidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5 µg/kg followed by 0.5 µg/kg/h until abdominal closure
Trial: 25863753
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (RT) with 30 Gy to the site of residual disease
Trial: 20024718
Drug: Self-selected treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-selected treatment partners
Trial: 20024718
Drug: Community-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based treatment partners
Trial: 20024718
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment partner
Trial: 17067318
Drug: Bimosiamose disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimosiamose disodium (2-140 mg single dose, 8-70 mg twice daily)
Trial: 17067318
Drug: Bimosiamose disodium
RxNorm normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bimosiamose disodium (doses > or =50 mg given twice daily and 105 mg once daily)
Trial: 15325680
Drug: High wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High wheat bran fiber (WBF) supplementation (13.5 g/d)
Trial: 15325680
Drug: Low wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low wheat bran fiber (WBF) supplementation (2 g/d)
Trial: 26942345
Drug: Investigational group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational group B streptococcal vaccine
Trial: 16645152
Drug: Oral E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NETA (1 mg/0.5 mg)
Trial: 16645152
Drug: Intranasal E2/NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal E2/NET
Trial: 17317046
Drug: Oral E2/NETA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral E2/NETA
Trial: 6385878
Drug: ticarcillin 3
RxNorm normalized name: ticarcillin 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin 3 grams every 4 hours and tobramycin 1.5 mg/kg every 8 hours
Trial: 25955866
Drug: DEX infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX infusion at 0.5 μg/kg/h for 10 min and then adjusted to 0.2 to 0.5 μg/kg/h
Trial: 25955866
Drug: DEX infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEX infusion
Trial: 11956353
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline infusion
Trial: 22202972
Drug: Daikenchuto (DKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (DKT) 7.5 g/day from the day after surgery until the 7th postoperative day
Trial: 16296572
Drug: nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol 5 mg once daily
Trial: 16296572
Drug: losartan 50
RxNorm normalized name: LOSARTAN 50MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: losartan 50 mg once daily
Trial: 12063454
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g before skin incision, 400 mg/h during operation, and 500 mg in pump priming)
Trial: 8582464
Drug: Hamamelis distillate
RxNorm normalized name: petroleum distillate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hamamelis distillate cream (5.35 g hamamelis distillate with 0.64 mg ketone/100 g)
Trial: 10397661
Drug: Drug-free vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-free vehicle
Trial: 27205
Drug: Orciprenaline (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orciprenaline (1.5 mg)
Trial: 31995130
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant medication in combination with cognitive behavioral therapy
Trial: 30935866
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment of LHRH-a)
Trial: 22226275
Drug: Pancreatic polypeptide
RxNorm normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic polypeptide (PP) infusion at 2 pmol/kg/min for 72 hours
Trial: 22226275
Drug: Pancreatic polypeptide
RxNorm normalized name: PANCREATIC POLYPEPTIDE
DrugBank: Pancreatic Polypeptide (DB12822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic polypeptide (PP) infusion
Trial: 19687024
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (GA and IFNbeta1b)
Trial: 15579335
Drug: Quadrivalent vaccine
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent vaccine (Rispoval 4)
Trial: 11499722
Drug: PVS-guided antiarrhythmic
RxNorm normalized name: PV
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PVS-guided antiarrhythmic drug therapy (n = 142)
Trial: 11499722
Drug: No antiarrhythmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiarrhythmic therapy (controls, n = 353)
Trial: 11499722
Drug: Propafenone (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (specific agent)
Trial: 7995387
Drug: Terbutaline via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline via p‐MDI (0.25 mg)
Trial: 7995387
Drug: Terbutaline via
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline via Turbuhaler (0.25 mg)
Trial: 2892739
Drug: Indomethacin suppositories
RxNorm normalized name: Indomethacin Suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin suppositories (2 X 100 mg)
Trial: 30974501
Drug: Restrictive transfusion
RxNorm normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive transfusion threshold (Hb < 75 g L‐1)
Trial: 30974501
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion threshold (Hb < 95 g L‐1 in intensive care and < 85 g L‐1 outside intensive care)
Trial: 23925396
Drug: Vaginal sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal sildenafil citrate (100 mg single dose)
Trial: 19309415
Drug: Clonidine (CLO),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (CLO), 0.1 mg or 0.15 mg b.i.d., for 6 days
Trial: 17372257
Drug: Reduction in
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduction in fasting insulin by 1 microunit/mL
Trial: 17372257
Drug: Participants with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with >39% body fat and >4.5 microunits/mL insulin levels
Trial: 17372257
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in body fat percentage or insulin over time
Trial: 13129740
Drug: Valsartan therapy
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan therapy for 8 weeks
Trial: 9185432
Drug: PCA+BI (Patient-Controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCA+BI (Patient-Controlled Analgesia with nighttime morphine infusion)
Trial: 8267401
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and postoperative chemotherapy (treatment A) [5-drug combination chemotherapy + tamoxifen]
Trial: 8267401
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and postoperative radiotherapy (treatment B)
Trial: 8267401
Drug: Responders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders to chemotherapy (treatment A)
Trial: 8267401
Drug: Non-responders to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-responders to chemotherapy (treatment A)
Trial: 3790404
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (SRT) administered under fasting conditions
Trial: 3790404
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (SRT) administered after a standardised breakfast
Trial: 3790404
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release theophylline (SRT) administered under fasting conditions in the evening (adults only)
Trial: 3790404
Drug: Intravenous theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous theophylline as a reference
Trial: 26676203
Drug: Immediate implants
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate implants placed in fresh sockets associated with chronic periapical disease (test group)
Trial: 24512981
Drug: Trabectedin 1.5mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.5mg/m2 24‐h intravenous infusion every 3 weeks (Arm A)
Trial: 24512981
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2 i.v., q3wk or doxorubicin 60 mg/m2 plus ifosfamide (6‐9 g/m2) i.v. q3wk (Arm B)